Lancet Child & Adolescent Health最新文献

{"title":"Dismantling barriers and biases against adolescent mothers","authors":"The Lancet Child & Adolescent Health","doi":"10.1016/S2352-4642(25)00105-1","DOIUrl":"10.1016/S2352-4642(25)00105-1","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 5","pages":"Page 283"},"PeriodicalIF":19.9,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial","authors":"Takudzwa S Sayi PhD , Umid M Sharapov , Zachary Matson MPH , Melissa M Coughlin PhD , Stephen N Crooke PhD , Qian An PhD , Jennifer K Knapp PhD , Asma Binte Aziz MBBS , Mohammad Yunus MSc CHDC , Warda Haque MSc , Sohel Rana MSc , Md Al Fazal Khan PhD , James P Alexander MD , Katrina Kretsinger , Paul A Rota PhD , Khalequ Zaman PhD , Abhijeet Anand MBBS","doi":"10.1016/S2352-4642(25)00090-2","DOIUrl":"10.1016/S2352-4642(25)00090-2","url":null,"abstract":"<div><h3>Background</h3><div>The first dose of measles–rubella (MR) vaccine is routinely administered to infants aged 9 months as part of a standard two-dose schedule. However, during large measles outbreaks and in other settings of increased circulation or increased risk, WHO recommends administering a supplementary dose at age 6 months to protect young infants. We aimed to assess the immunogenicity and safety of a first dose of MR vaccine administered to infants aged 6 months and its effect on the immune response to the routine MR vaccine at age 9 months.</div></div><div><h3>Methods</h3><div>This open-label, randomised trial enrolled healthy infants aged 6 months in Matlab, Bangladesh, who had never received an MR vaccine dose and had no history of measles or rubella. Using a computer-generated block randomisation scheme, infants were randomly assigned (1:1) to receive either two doses of the MR vaccine, one at age 6 months and the second at age 9 months (two-dose group), or one dose at age 9 months (one-dose group). Baseline characteristics were recorded for all enrolled participants at age 6 months. Blood samples were drawn for antibody assays before each vaccination and at final follow up when infants were aged 11 months. The primary outcome was immunogenicity of a first MR vaccine in infants aged 6 months or 9 months and the immunogenicity of a second MR vaccine in infants aged 9 months who received their first MR vaccine at 6 months. Immunogenicity was measured as the proportion of infants who seroconverted in the 12 weeks after vaccination at age 6 months or the 8 weeks after vaccination at age 9 months. Seroconversion was defined as a 4-times increase in IgG concentrations relative to the pre-vaccination concentrations or achieving seroprotective antibody concentrations between study timepoints. The modified intention-to-treat analysis included all infants who received MR vaccines per group assignment and had antibody results at baseline, 9 months, and 11 months. All enrolled infants were included in the safety analysis of the immediate reactions (observed by study staff at the fixed-site clinic in the first 30 min after vaccination), adverse events within 48 h of vaccination among infants in the two-dose group receiving their first MR vaccine at age 6 months, and adverse events observed by study staff or parents at any time during the study. The trial is registered on <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, <span><span>NCT03071575</span><svg><path></path></svg></span>, and is closed to enrolment.</div></div><div><h3>Findings</h3><div>Between March 9, 2017, and March 18, 2018, 620 infants were enrolled and randomly assigned to the two study groups (312 in the two-dose group and 308 in the one-dose group). Of the 301 infants vaccinated at 6 months, 282 seroconverted for measles (94%, 95% CI 90–96), and 283 seroconverted for rubella (94%, 91–96). By 11 months, after receiving a second dose at age 9 months, 297","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 5","pages":"Pages 306-314"},"PeriodicalIF":19.9,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging nutritional rehabilitation and tuberculosis programmes to tackle tuberculosis and severe acute malnutrition in children","authors":"Bryan J Vonasek , Olivier Marcy , Jasmine Armour-Marshall , Martina Casenghi , Cécile Cazes , Mohammod Jobayer Chisti , Marc d’Elbée , Helena Huerga , Cathy Hewison , Christina L Lancioni , Patrick S Lungu , Eric D McCollum , Victor Musiime , Tisungane Mvalo , James A Seddon , Andrew P Steenhoff , Tania A Thomas , Marco Tovar , Anca Vasiliu , Anthony Garcia-Prats , Chishala Chabala","doi":"10.1016/S2352-4642(25)00062-8","DOIUrl":"10.1016/S2352-4642(25)00062-8","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 5","pages":"Pages 292-294"},"PeriodicalIF":19.9,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of depressive symptoms among young people in London, UK, and Tokyo, Japan: a longitudinal cross-cohort study","authors":"Gemma Knowles PhD , Daniel Stanyon MSc , Syudo Yamasaki PhD , Mitsuhiro Miyashita PhD , Charlotte Gayer-Anderson PhD , Kaori Endo PhD , Satoshi Usami PhD , Junko Niimura PhD , Naomi Nakajima PhD , Kaori Baba PhD , Thai-sha Richards , Jonas Kitisu , Adna Hashi , Karima Shyan Clement-Gbede , Niiokani Tettey , Samantha Davis MSc , Katie Lowis MSc , Verity Buckley MSc , Dario Moreno-Agostino PhD , Esther Putzgruber MSc , Atsushi Nishida PhD","doi":"10.1016/S2352-4642(25)00059-8","DOIUrl":"10.1016/S2352-4642(25)00059-8","url":null,"abstract":"<div><h3>Background</h3><div>Research suggests gender inequalities in adolescent mental health are context dependent and might be preventable through social and structural change. However, variations in the size of gender inequalities in mental health across diverse cultural contexts could be due to incomparable measurement. We aimed to compare a measurement of mental health among young people in Tokyo, Japan, and London, UK, and test the hypothesis that gender inequalities in depressive symptom trajectories are larger in London than in Tokyo.</div></div><div><h3>Methods</h3><div>For this longitudinal cross-cohort study, we extracted responses to the 13-item Short Mood and Feelings Questionnaire (SMFQ) by young people who participated in three consecutive waves of the Tokyo Teen Cohort (TTC) and the London-based Resilience, Ethnicity and Adolescent Mental Health (REACH) cohorts. We used multigroup and longitudinal confirmatory factor analysis to examine measurement invariance of the SMFQ by cohort, gender, and age. Latent growth curve models were used to estimate and compare mean trajectories of SMFQ from ages 11–16 years among boys and girls, overall, and in each cohort.</div></div><div><h3>Findings</h3><div>7100 young people from TTC and REACH (3587 boys [50·5%] and 3513 girls [49·5%]) were included in the analysis. With the TTC and REACH cohorts combined, we found very strong evidence of differences in SMFQ between boys and girls, with a mean starting level of 0·71 points (95% CI 0·42–0·95) higher and mean rate of change of 0·73 points (95% CI 0·62–0·82) higher in girls versus boys. Among the 4287 participants in REACH (2097 [48·9%] boys and 2190 [51·1%] girls), a difference in SMFQ was evident between boys and girls at age 11–12 years (difference in mean intercepts: 0·75 [95% CI 0·25–1·25]). Among the 2813 participants in TCC (1490 boys [53·0%] and 1323 girls [47·0%]), differences in SMFQ between boys and girls emerged at a later age, between ages 11 years and 14 years, during which SMFQ decreased among boys and increased among girls (mean difference in slopes 0·52 [95% CI 0·40 to 0·65]). The difference in SMFQ between boys and girls widened year-on-year in both cohorts; by age 16 years, the difference in SMFQ between boys and girls in REACH (mean difference in slopes 0·98 [95% CI 0·77 to 1·20]) was around twice as large as in TTC (0·52 [0·40 to 0·65]). The annual rate of increase in SMFQ among girls in REACH (1·1 [95% CI 0·9–1·3]) was around four times greater than among girls in TTC (0·3 [0·2–0·4]). We found little evidence to suggest these differences in gender inequalities were due to incomparable measurement.</div></div><div><h3>Interpretation</h3><div>Gender inequalities in emotional health among young people are context dependent and might be preventable through social and structural change.</div></div><div><h3>Funding</h3><div>Japanese Society for the Promotion of Science, UK Economic and Social Research Council, and European Research","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Pages 224-233"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ben Perks: we can end childhood trauma","authors":"Jules Morgan","doi":"10.1016/S2352-4642(25)00071-9","DOIUrl":"10.1016/S2352-4642(25)00071-9","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Page 222"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas","authors":"Hylke Waalewijn PhD ,&nbsp;Mounier Almett MSc ,&nbsp;Roeland E Wasmann PhD ,&nbsp;Tim R Cressey PhD ,&nbsp;Prof Philippa Easterbrook MPH ,&nbsp;Peter Ehizibue Olumese MD ,&nbsp;Prof Anneke C Hesseling PhD ,&nbsp;Anthony J Garcia-Prats MD ,&nbsp;Prof Joel Tarning PhD ,&nbsp;Anna Turkova MRCPCH ,&nbsp;Kerri Viney PhD ,&nbsp;Elin M Svensson PhD ,&nbsp;Angela Colbers PhD ,&nbsp;Wilson M Were MMed ,&nbsp;Prof Paolo Denti PhD ,&nbsp;Martina Penazzato PhD","doi":"10.1016/S2352-4642(25)00025-2","DOIUrl":"10.1016/S2352-4642(25)00025-2","url":null,"abstract":"<div><div>Generally, dose recommendations for children are expressed as fixed dosing increments related to bodyweight, known as weight bands. The weight bands recommended in WHO treatment guidelines vary between diseases, leading to complexity and potential dosing errors when treating children for multiple diseases simultaneously. The introduction of a harmonised weight banding approach for orally administered drugs across disease areas could streamline dosing for young children, but implementing such an approach would require changes in current dosing recommendations. In this Health Policy, we describe the process we conducted to: identify therapeutic areas for harmonisation of weight bands; propose a harmonised weight-banding system to align with current use of weight bands in antibiotic guidance; and simulate the expected effect of dose adjustments due to weight-band harmonisation. Each step of this process, along with the effect and feasibility of weight-band harmonisation was discussed with clinical, policy, and pharmacology experts convened by WHO, representing four therapeutic areas: tuberculosis, HIV, malaria, and hepatitis C. Dosing according to harmonised weight bands across the targeted therapeutic areas was found to be feasible and should be considered for implementation by WHO disease programmes through their appropriate normative processes.</div></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Pages 274-282"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth of children who are HIV-exposed but uninfected: a systematic review and meta-analysis","authors":"Gabriel Loni Ekali PhD ,&nbsp;Pascal Roland Enok Bonong PhD ,&nbsp;Cyprien Kengne-Nde MSc ,&nbsp;Julie Jesson PhD ,&nbsp;Ceri Evans PhD ,&nbsp;Prof Andrew J Prendergast DPhil ,&nbsp;Valériane Leroy PhD","doi":"10.1016/S2352-4642(25)00027-6","DOIUrl":"10.1016/S2352-4642(25)00027-6","url":null,"abstract":"<div><h3>Background</h3><div>Pooled analyses summarising long-term growth outcomes in children who are HIV-exposed uninfected (HEU) compared with children who are HIV-unexposed (HU) are lacking. We aimed to summarise the existing literature on growth outcomes.</div></div><div><h3>Methods</h3><div>We did a systematic review and meta-analysis of published literature on 60-month growth outcomes (length-for-age Z score [LAZ], weight-for-age Z score [WAZ], weight-for-length Z score [WLZ], head circumference-for-age Z score [HCAZ], stunting [LAZ&lt;−2], wasting [WLZ&lt;−2], underweight [WAZ&lt;−2], and microcephaly [HCAZ&lt;−2]) in children who were HEU compared with children who were HU. Medline, EMBASE, Cochrane Library, WHO Global Index Medicus and Web of Science were searched from Jan 1, 1989 to Dec 31, 2022. Randomised controlled trials and cohort studies comparing growth in children who were HEU versus children who were HU were included. Study-specific estimates were pooled by use of random-effects and fixed-effect meta-analysis. Results were stratified by age (birth; 0–5 months; 6–11 months; 12–17 months; 18–23 months; and 24–60 months) and antiretroviral therapy (ART) period (pre-ART [before 2003]; ART [2003 onwards]). This study is registered with PROSPERO, CRD42018091762.</div></div><div><h3>Findings</h3><div>28 studies were included; 25 (90%) were done in Africa and 23 (82%) in the ART period, reporting growth outcomes on 11 794 children who were HEU and 23 826 children who were HU from 15 countries. Across all ages in the pre-ART and ART periods, children who were HEU had significantly lower LAZ compared with children who were HU. In the ART period, children who were HEU were more likely to be stunted at all ages except for 0–5 months. Pre-ART, significantly lower WAZ was found in children who were HEU from 6–11 months to 18–23 months, and at all ages during the ART period. Children who were HEU had significantly higher odds of underweight at birth than children who were HU; this difference persisted to age 2 years. Pre-ART and ART HCAZ were significantly lower for children who were HEU at all ages, except for 24–60 months, even though heterogeneity was high. No differences in WLZ were found between groups. Differences between children who were HEU and children who were HU tended to be more pronounced during the ART period compared with the pre-ART period, particularly at younger ages.</div></div><div><h3>Interpretation</h3><div>Children who are HEU have more growth faltering than children who are HU, which is present at birth and persists over the first 24 months. These growth disparities remain evident during the ART period. Interventions to promote healthy growth probably need to start antenatally.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Pages 234-247"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthy skin for children and young people with skin of colour starts with clinician knowledge and recognition: a narrative review","authors":"Bernadette M Ricciardo MBBS FACD ,&nbsp;Heather-Lynn Kessaris BSc MD ,&nbsp;Prof Sarah Cherian MBBS PhD ,&nbsp;Prof S Prasad Kumarasinghe MBBS FACD ,&nbsp;Ingrid Amgarth-Duff PhD ,&nbsp;Dasmesh Sron BCom MD ,&nbsp;Prof Regina Oladokun MBBS FMCPaed ,&nbsp;Artiene H Tatian MBBS FACD ,&nbsp;Prof Asha C Bowen MBBS PhD","doi":"10.1016/S2352-4642(24)00356-0","DOIUrl":"10.1016/S2352-4642(24)00356-0","url":null,"abstract":"<div><div>Skin conditions most frequently encountered in paediatric practice include infections, infestations, atopic dermatitis, and acne. Skin of colour refers to skin with increased melanin and darker pigmentation, and reflects global racial and ethnic diversity. Managing skin conditions in skin of colour requires health equity nuance, which is rarely explicitly taught. Awareness of the demographic factors, social determinants of health, and cultural practices that affect prevalence, morphological differences, and treatment of skin conditions is imperative. In this Review, we present the burden and clinical features of the common childhood skin conditions impetigo, scabies, head lice, tinea, atopic dermatitis, and acne in skin of colour. Paediatricians play an important role in diagnosis and management of these conditions to improve quality of life and prevent downstream complications, but they require education around skin of colour. We also discuss the systemic and structural racism, and the environmental and socioeconomic disadvantage, that perpetuate skin health inequity in communities with skin of colour.</div></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Pages 262-273"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Child Adolesc Health 2025; 9: 9","authors":"","doi":"10.1016/S2352-4642(25)00072-0","DOIUrl":"10.1016/S2352-4642(25)00072-0","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Page e12"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143641850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study","authors":"Prof Regino P Gonzalez-Peralta MD ,&nbsp;Prof Jessica W Wen MD ,&nbsp;Prof Winita Hardikar FRACP PhD ,&nbsp;Prof Wikrom W Karnsakul MD ,&nbsp;Prof Suzanne Whitworth MD ,&nbsp;Prof Chuan-Hao Lin MD ,&nbsp;Prof Giuseppe Indolfi MD PhD ,&nbsp;Prof Philip Rosenthal MD ,&nbsp;Prof William Balistreri MD ,&nbsp;Prof Kathleen B Schwarz MD ,&nbsp;Jonathan R Honegger MD ,&nbsp;Xu Zhang PhD ,&nbsp;Evguenia C Svarovskaia PhD ,&nbsp;Vithika Suri MSc ,&nbsp;Kathryn Kersey MSc ,&nbsp;Prof Daniel H Leung MD FAAP","doi":"10.1016/S2352-4642(25)00028-8","DOIUrl":"10.1016/S2352-4642(25)00028-8","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Direct-acting antiviral treatment is associated with high rates of sustained virological response and has a favourable safety profile in children aged 3–17 years with chronic hepatitis C virus (HCV) infection, but data describing the durability of sustained virological response and its effects on growth and sexual development are needed. This study aimed to assess the efficacy and long-term effects of sofosbuvir-based direct-acting antiviral regimens on growth and development in the paediatric population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this international, multicentre, observational registry study, children aged 3–17 years with HCV who received sofosbuvir plus ribavirin, ledipasvir plus sofosbuvir with or without ribavirin, sofosbuvir plus velpatasvir, or sofosbuvir plus velpatasvir plus voxilaprevir in previous clinical trials were eligible for follow-up of growth and sexual development parameters for up to 5 years. Registry baseline was documented as the last follow-up visit under the parent study protocol and follow-up consisted of clinical visits every 6 months for the first 2 years and every 12 months thereafter for up to 5 years, during which symptom-directed physical examination, height and weight measurements, Tanner pubertal stage assessment, procedure-related adverse events documentation, and blood sampling collection were completed. The primary endpoints were changes, relative to baseline, in height, weight, BMI Z scores, and Tanner pubertal stage. Height, weight, BMI, and corresponding percentiles and Z scores were summarised using descriptive statistics. The study was registered at ClinicalTrials.gov (NCT02510300).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between October 2015 and June 2021, 461 participants were enrolled in the registry. 426 (92%) participants had at least one post-baseline assessment and were included in the analysis. 93 (20%) participants were previously treated with sofosbuvir plus ribavirin, 192 (42%) with ledipasvir plus sofosbuvir with or without ribavirin, 158 (34%) with sofosbuvir plus velpatasvir, and 18 (4%) with sofosbuvir plus velpatasvir plus voxilaprevir. Most participants included in the analysis were female (247 [58%] participants; sex assigned at birth) and White (342 [80%] participants). The most common HCV genotypes were GT1 (281 [66%] participants) and GT3 (88 [21%] participants). Clinical assessments continued until January 2023. The median follow-up was 3·7 years (IQR 2·7–4·6) among the 426 participants, 302 (71%) of whom completed at least 3 years of follow-up. 424 (&gt;99%) of 426 participants had previously achieved sustained virological response during their parent studies. With a mean age of 12 years (SD 4·1) at baseline, the median change in median Z scores during follow-up was 0·0 (IQR −0·2 to 0·4) for height, 0·1 (−0·3 to 0·5) for weight, and 0·0 (−0·3 to 0·5) for BMI. Increases in Tanner stage were consistent with age, regardless of sex or which seconda","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 4","pages":"Pages 248-254"},"PeriodicalIF":19.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}